2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
申请人:Wu Gang
公开号:US20060111414A1
公开(公告)日:2006-05-25
Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure
or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R
1
, R
2
, Y and Z are defined herein.
提供了新型化合物,这些化合物是糖原磷酸化酶抑制剂,可用于治疗、预防或减缓需要糖原磷酸化酶抑制剂治疗的疾病,如糖尿病及相关症状(如高血糖、糖耐量受损、胰岛素抵抗和高胰岛素血症),与糖尿病相关的微血管并发症(如视网膜病变、神经病变、肾病和延迟愈合伤口),与糖尿病相关的大血管并发症(心血管疾病,如动脉粥样硬化、心脏功能异常、心肌缺血和中风),以及代谢综合征及其组成症状,包括高血压、肥胖和脂质代谢异常(包括高三酸甘油脂血症、高胆固醇血症和低高密度脂蛋白血症),以及其他疾病,如非心脏缺血、感染和癌症。这些新型化合物具有结构、立体异构体、前药或其药用盐,其中W、R1、R2、Y和Z在此处定义。